159、超越运动症状分期:元律医学帕金森病神经—代谢状态的多模态动态计算( Beyond Motor Symptom Staging: Multimodal Dynamic Computation of Neuro-Metabolic States in Parkinson's Disease Using Prim-Lex Medicine)

Parkinson‘s disease (PD) is among the fastest-growing neurological causes of disability worldwide. The Global Burden of Disease Study projects 25.2 million people living with PD by 2050 (95% uncertainty interval 21.7–30.1 million), a 112% increase from 2021, with population ageing contributing approximately 89% of the growth. Dopaminergic replacement remains the therapeutic cornerstone for short-term motor control, but it does not delay disease progression, long-term levodopa is complicated by motor fluctuations and dyskinesia, and non-motor symptoms remain inadequately addressed. At the diagnostic level, the MDS clinical criteria remain foundational, yet motor manifestations become evident only after 60–80% loss of substantia nigra pars compacta dopaminergic neurons. The emergence of α-synuclein seed amplification assays (SAA) and biological definition frameworks—NSD-ISS and SynNeurGe—has made it possible to identify PD at a “biologically early phase,” but their clinical applicability, capacity to capture clinical–biological complexity, and the ethical risks of premature clinical deployment remain actively contested. Adaptive deep brain stimulation (aDBS) received FDA approval in February 2025, marking the entry of closed-loop neuromodulation into routine practice, yet its control policy remains anchored to a single beta-band biomarker and manually set thresholds, without integration of multi-system state information. Against this background, this paper develops a Prim-Lex Parkinson’s Disease Multimodal Clinical Framework. The framework uses the Fivefold Prim-Fire of Prim-Lex Theory as theoretical background, Five-Element computation as the organizing language for functional modules, Eight-Dimensional States as the clinical information description layer, and Nine-Nexus Guidance as a research-oriented decision-support layer. The core contribution is threefold. First, theory development and boundary specification: terms such as “Prim-Fire,” “coherence,” and “decoherence” are strictly operationalized as statistical constructs or theoretical background; the animal life Prim-Fire level is identified as the only level directly relevant to PD clinical questions; and prior claims of “quantum coherence,” “irreversible phase transition,” and “NADH/NAD⁺ imbalance as the initiating root cause” are explicitly abandoned as exceeding available evidence. Second, clinical evidence mapping: a four-tier grading system (E1–E4) distinguishes human PD evidence supported by guidelines or high-quality systematic reviews, observational candidate associations, indirect evidence from human non-PD or mechanistic studies, and hypotheses derived solely from animal/in vitro or theoretical reasoning. Third, a falsifiable validation protocol: H1 (incremental predictive value) is the primary test, specifying whether Eight-Dimensional indices provide reproducible, calibrated, and clinically net-beneficial information beyond conventional PD clinical variables; falsification conditions are pre-specified and cannot be circumvented by changing outcomes, subgroups, or thresholds. The anticipated contribution is not a new PD therapy, nor a claim that Prim-Lex Theory has uncovered the “root mechanism” of PD. Its value lies in providing an operationalizable, falsifiable, and methodologically auditable theory–measurement–validation loop for the multi-system assessment of PD, enabling independent replication, testing, or refutation by neurology, neuromodulation, and clinical prediction model communities. All mathematical expressions are constrained by explicit definitions, units, directionality, missing-data rules, and evidence grading; thresholds not calibrated in independent PD cohorts are presented as exploratory parameters only.